Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

11.85 +0.62 (+5.52%)
Delayed Quote Updated: 12:54 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Preview: Arcturus Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics (NASDAQ:ARCT) Reports Mixed Q3 2025 Results, Extends Cash Runway to 2028 ↗
Arcturus Q3 2025 results show a revenue miss but a smaller-than-expected loss. The company advances its CF and OTC programs, with cash extending into 2028. 
Via Chartmill
News headline image
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
This Molina Healthcare Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Cathie Wood Goes Shopping: 3 Stocks She Just Bought ↗
The growth-focused money manager only bought three stocks on Wednesday. Let's check out that shopping list. 
Via The Motley Fool
Topics ETFs
News headline image
Where Arcturus Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture ↗
Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement. 
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Crude Oil Gains Over 1%; AT&T Shares Slide After Q3 Results ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Dow Falls 100 Points; Netflix Shares Tumble On Downbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Arcturus Therapeutics Stock Plunges Over 57% Today: What’s Causing The Sell-Off? ↗
The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing. 
Via Stocktwits
News headline image
Arcturus Crashes 55% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis Drug ↗
The company is working on a treatment for cystic fibrosis using messenger RNA, or mRNA, technology. 
Via Investor's Business Daily
News headline image
Wednesday's pre-market session: top gainers and losers ↗
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
MissionIRNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Jumps as ARK Invest Buys $49.7M Stake, Trims Roku and Tempus AI
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225% ↗
On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA), 
Via Benzinga
Topics Artificial Intelligence
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.